Solvated form of trilaciclib dihydrochloride

The solvated form of trilaciclib dihydrochloride acetic acid hemisolvate addresses the need for high purity and stability in trilaciclib, enabling effective cancer treatment by providing a crystalline form with controlled impurity profiles and enhanced solubility through industrializable processes.

WO2024241152A1PCT designated stage expired Publication Date: 2024-11-28OLON SPA
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/IB2024/054718
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-19
Filing Date
2024-05-15
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

There is a need for a form of trilaciclib active ingredient characterized by high purity and stability, along with an easily industrializable process that allows control of the impurity profile, particularly for use in chemotherapy-induced myelosuppression and cancer treatment.

Method used

A solvated form of trilaciclib dihydrochloride acetic acid hemisolvate in crystalline form is developed, along with two alternative preparation processes that ensure high purity, stability, and controlled impurity profiles, facilitating industrial-scale production and enhanced solubility.

Benefits of technology

The solvated form of trilaciclib dihydrochloride acetic acid hemisolvate achieves high purity and stability, with controlled impurity profiles, and is suitable for industrial production, offering improved solubility and efficacy in cancer treatments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000002_0001
    Figure IMGF000002_0001
  • Figure IMGF000003_0001
    Figure IMGF000003_0001
  • Figure IMGF000004_0001
    Figure IMGF000004_0001
Patent Text Reader

Abstract

The present invention refers to the technical field of active pharmaceutical ingredients. Specifically, the present invention concerns a solvated form of the active ingredient trilaciclib dihydrochloride, in particular trilaciclib dihydrochloride acetic acid hemisolvate of formula II in crystalline form. Advantageously, this solvated form is characterized by high purity and stability, as well as high solubility. The present invention also concerns two alternative processes for the preparation of said solvated form of trilaciclib dihydrochloride. This process allows for advantageous industrialization and control of the impurity profile of the final product.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] SOLVATED FORM OF TRILACICLIB DIHYDROCHLORIDE

[0002] TECHNICAL FIELD

[0003] The present invention refers to the technical field of active pharmaceutical ingredients. Specifically, the present invention concerns a solvated form of the active ingredient trilaciclib dihydrochloride, in particular trilaciclib dihydrochloride acetic acid hemisolvate of formula II in crystalline form, and two alternative preparation processes.

[0004] PRIOR ART

[0005] Trilaciclib dihydrochloride is an active ingredient having formula I Formula I .

[0006] This active ingredient, as is known, is capable of temporarily halting normal cells to prevent chemotherapy-induced myelosuppression and therefore to improve anti-tumor efficacy. It can be used, for example, in patients with small cell lung cancer (SOLO) receiving topotecan-based chemotherapy.

[0007] In particular, US 8,598,186; US 8,598,197; US 9,957,276; US 10,189,849 and US 10,189,850 and the corresponding WO 2012 / 061156 describe a class of inhibitors of cyclin- dependent N- (heteroaryl ) -pyrrolo [ 3 , 2-d] pyrimidin-2- amine kinases including 2 ' - ( ( 5- ( 4-methylpiperazyl-l- yl ) pyri din-2 -yl ) amino ) -7 ' , 8 ' -dihydro- 6 ' H- spiro [ cyclohexane- 1 , 9 ' -pyrazino [ 1 ' , 2 : 1 , 5 ] pyrrolo [ 2 , 3- d] pyrimidin] - 6 ' -one ( Compound 1 ) Compound 1 .

[0008] Furthermore , US 2019 / 135820 and WO 2020 / 041770 describe processes for the synthesis of Compound 1 . Compound 1 , referred to as "G1T28" or " trilaciclib" , transiently halts normal cells to prevent chemotherapy-induced myelosuppression, thereby improving anti-tumor ef ficacy . Its use is envisaged, for example , in patients with small cell lung cancer ( SCLC ) undergoing chemotherapy with topotecan, as well as in combination with etoposide and carboplatin in SCLC . Additionally, compound 1 is used in human clinical trials for the treatment of triplenegative breast cancer in combination with standard of care for neoadj uvant treatment of breast cancer .

[0009] There is therefore a need to have a form of trilaciclib active ingredient which is characteri zed by high purity and stability, as well as a process to produce it which is easily industriali zable and which allows the impurity profile associated with the product obtained to be controlled .

[0010] SUMMARY OF THE INVENTION

[0011] The Applicant has now found a new solvated form o f trilaciclib, in particular trilaciclib dihydrochloride acetic acid hemisolvate of formula I I in crystalline form, which satis fies the aforementioned needs . Therefore , in accordance with a first aspect , the present invention concerns trilaciclib dihydrochloride acetic acid hemisolvate of formula I I in crystalline form Formula I I , according to the attached claims .

[0012] In accordance with a second aspect , the present invention concerns a process for obtaining trilaciclib dihydrochloride acetic acid hemisolvate of formula I I in crystalline form Formula I I , according to the attached claims . In accordance with a third aspect , the present invention concerns a further proce ss for obtaining trilaciclib dihydrochloride acetic acid hemisolvate of formula I I in crystalline form Formula I I , according to the attached claims .

[0013] Advantageously, the solvated form of trilaciclib dihydrochloride , in particular trilaciclib dihydrochloride acetic acid hemisolvate of formula I I in crystalline form, is characteri zed by high purity and stability, as well as high solubility . The solvated form of this active ingredient with such characteristics is advantageously obtained through the processes according to the present invention . The processes according to the present invention in fact allow an advantageous control of impurity profile on the final product . Furthermore , the two processes of the invention are both suitable for implementation on an industrial scale as they can be easily industrialized .

[0014] Further aspects , features and advantages of the invention will be evident from the following detailed description .

[0015] BRIEF DESCRIPTION OF THE FIGURES

[0016] Figure 1 shows the X-ray di f fraction (XRPD) spectrum of trilaciclib dihydrochloride acetic acid hemisolvate of the invention;

[0017] Figure 2 shows the results of the TGA thermogravimetric analysis performed on trilaciclib dihydrochloride acetic acid hemisolvate of the invention;

[0018] Figure 3 shows the1H-NMR hydrogen nuclear magnetic resonance spectrum of trilaciclib dihydrochloride acetic acid hemisolvate of the invention .

[0019] DETAILED DESCRIPTION

[0020] For the purposes of the invention, definitions of some terms and / or expressions used in this description and in the claims will be provided below .

[0021] A first aspect of the invention therefore concerns trilaciclib dihydrochloride acetic acid hemisolvate of formula I I in crystalline form having a characteristic XRPD dif f ractogram comprising at least one characteristic peak expressed in 2-Theta (20) values selected from 7,2°±0,2°, 14,5°±0,2°, 15,9°±0,2°, 18,2°±0,2°, 18,9°±0,2° e 22,l°±0,2°.

[0022] Preferably, the solvate of formula II in crystalline form has a characteristic XRPD dif f ractogram comprising at least two characteristic peaks expressed in 2-Theta (26) values selected from 7,2°±0,2°, 14,5°±0,2°, 15,9°±0,2°, 18,2°±0,2°, 18,9°±0,2° e 22,l°±0,2°.

[0023] More preferably, the solvate of formula II in crystalline form has a characteristic XRPD dif f ractogram comprising at least three characteristic peaks expressed in 2-Theta (26) values selected from 7,2°±0,2°, 14,5°±0,2°, 15,9°±0,2°, 18,2°±0,2°, 18,9°±0,2° e 22,l°±0,2°.

[0024] Even more preferably, the solvate of formula II in crystalline form has a characteristic XRPD dif f ractogram comprising at least four characteristic peaks expressed in 2-Theta (20) values selected from 7,2°±0,2°, 14,5°±0,2°, 15,9°±0,2°, 18,2°±0,2°, 18,9°±0,2° e 22, l°±0, 2° .

[0025] According to a preferred embodiment of the invention, the solvate of formula II in crystalline form has a characteristic XRPD dif f ractogram comprising or consisting of the following characteristic peaks expressed in 2-Theta (26) values 7,2°±0,2°, 14,5°±0,2°, 15,9°±0,2°, 18,2°±0,2°, 18,9°±0,2° e 22,l°±0,2°. In addition, as additional peak(s) , the solvate of formula II in crystalline form may further comprise at least one characteristic peak expressed in 2-Theta (20) values selected from 13, l°±0, 2°, 15,0°±0,2°, 20.6°±0,2°, 25, 6°±0, 2° .

[0026] The solvated form according to the invention, i.e. trilaciclib dihydrochloride acetic acid hemisolvate of formula II, has a molar ratio between trilaciclib dihydrochloride and acetic acid equal to 1:0.5.

[0027] With reference to the final pharmaceutical formulations of trilaciclib, administered intravenously, the active ingredient trilaciclib dihydrochloride acetic acid hemisolvate of formula II of the present invention is particularly advantageous thanks to its high solubility compared to other less soluble forms, for example trilaciclib free base.

[0028] Another aspect of the invention concerns a process for obtaining trilaciclib dihydrochloride acetic acid hemisolvate of formula II in crystalline form Formula II as defined above, comprising the steps of: a' ) suspending trilaciclib base in acetic acid and adding hydrochloric acid, obtaining a suspension of trilaciclib dihydrochloride, or a' ’ ) suspending trilaciclib in the form of a salt in acetic acid, wherein said salt is not trilaciclib dihydrochloride, and adding hydrochloric acid, obtaining a suspension of trilaciclib dihydrochloride, or a' ' ' ) suspending trilaciclib dihydrochloride in acetic acid, obtaining a suspension of trilaciclib dihydrochloride ; b) adding the suspension of trilaciclib dihydrochloride obtained in point a' ) , a' ' ) or a' ' ' ) to an organic solvent so as to precipitate trilaciclib as trilaciclib solvate of formula II in crystalline form; c) isolating trilaciclib solvate of formula II in crystalline form.

[0029] With reference to step a' ) , a' ' ) or a' ' ' ) , trilaciclib is preferably trilaciclib free base or a salt thereof. Preferably the trilaciclib salt is dihydrochloride or trifluoro acetate.

[0030] According to a preferred aspect of the invention, in step a' ) , a' ' ) or a' ' ' ) the ratio of trilaciclib to acetic acid is comprised between 1:4 and 1:8 by volume. Preferably, said ratio is comprised between 1:5 and 1:7. According to a particularly preferred aspect, said ratio is 1:6.

[0031] According to another preferred aspect of the invention, the step a' ) , a' ') or a' ' ' ) is carried out at a temperature comprised between 15°-35°C. Preferably, the temperature at which step a' ) , a' ' ) or a' ' ' ) is carried out is comprised between 22°-28°C.

[0032] As regards steps a' ) and a' ' ) , preferably the hydrochloric acid is anhydrous hydrochloric acid dissolved in an organic solvent selected from alcohols, ethers, esters or mixtures thereof. When the anhydrous hydrochloric acid is dissolved in an alcohol, this is preferably selected from methanol, ethanol, isopropanol or mixtures thereof, more preferably the anhydrous hydrochloric acid is in isopropanol. When anhydrous hydrochloric acid is dissolved in an ether, this is preferably cyclopentyl methyl ether. When anhydrous hydrochloric acid is dissolved in an ester, this is preferably ethyl acetate, isopropyl acetate or mixtures thereof .

[0033] According to a preferred aspect, the concentration of anhydrous hydrochloric acid in solvent is comprised between 10-25% by weight, preferably the concentration of hydrochloric acid in isopropanol is comprised 15-19% by weight.

[0034] As regards step b) , preferably the ratio of the suspension obtained in step a' ) , a' ' ) or a' ' ' ) to the organic solvent is between 1:1 and 1:3 by volume, preferably such ratio is 1:2 by volume.

[0035] According to a preferred aspect, the addition referred to in step b) takes place at a temperature comprised between 15° and 35°C, preferably comprised between 22° and 28 °C.

[0036] As regards step b) , the organic solvent is preferably selected from ethers and esters. Preferably, when the solvent is an ether, it has the formula OR1R2, wherein the R1 and R2 groups are selected, independently of each other, between C1-C6 alkyl, linear or branched, and C3- C6 cycloalkyl.

[0037] According to a preferred aspect, when the solvent is an ether, it is cyclopentyl methyl ether.

[0038] Preferably, when the solvent is an ester, it is selected from ethyl acetate and isopropyl acetate.

[0039] Advantageously, step b) is carried out in such a way as to dilute the suspension of trilaciclib dihydrochloride obtained in the previous point a' ) , a' ' ) or a' ' ' ) , so as to obtain the precipitation of trilaciclib dihydrochloride acid acetic hemisolvate of formula II and therefore increase the yields of the process.

[0040] As regards step c) of isolation, this step is preferably carried out by filtration.

[0041] According to a preferred aspect, the process of the invention further comprises a step d) : d) drying the solvate of formula II obtained in step c) under vacuum at a temperature comprised between 45°C and 60°C, preferably at a temperature comprised between 48 °C and 58°C, more preferably comprised between 50°C and 55 °C.

[0042] According to another preferred aspect, the drying step d) takes place for a time comprised between 10 and 48 hours, preferably comprised between 12 and 24 hours.

[0043] According to another preferred aspect, the drying step d) takes place at a temperature comprised between 45°C and 60°C, preferably at a temperature comprised between 48°C and 58°C, more preferably comprised between 50°C and 55°C, and for a time comprised between 10 and 48 hours, preferably comprised between 12 and 24 hours.

[0044] Another aspect of the invention concerns a further alternative process for obtaining the solvate of formula II in crystalline form. In particular, according to another aspect, the invention concerns a process for obtaining the solvate of formula II in crystalline form Formula II as defined above, comprising the steps of: m' ) suspending trilaciclib base in a mixture of organic solvent and acetic acid and adding hydrochloric acid, obtaining a suspension of trilaciclib dihydrochloride, or m' ' ) suspending trilaciclib in the form of salt in a mixture of organic solvent and acetic acid, wherein said salt is not trilaciclib dihydrochloride, and adding hydrochloric acid, obtaining a suspension of trilaciclib dihydrochloride, or m' ' ' ) suspending trilaciclib dihydrochloride in a mixture of organic solvent and acetic acid, obtaining a suspension of trilaciclib dihydrochloride; n) heating the suspension referred to in step m' ) , m' ' ) or m' ' ' ) to a temperature comprised between 50°C and 70°C, preferably comprised between 55°C and 65°C to obtain a suspension; o) cooling the suspension referred to in step n) to a temperature comprised between 0°C and 30°C, preferably comprised between 15°C and 30°C, more preferably between 22°C and 28°C; p) isolating trilaciclib solvate of formula II in crystalline form.

[0045] With reference to step m' ) , m' ' ) or m' ' ' ) , trilaciclib is preferably trilaciclib free base or a salt thereof. Preferably, the trilaciclib salt is dihydrochloride or trifluoro acetate.

[0046] According to a preferred aspect of the invention, in step m' ) , m' ' ) or m' ' ' ) , the ratio of trilaciclib : organic solvent : acetic acid is comprised between 1:10:3 and 1:20:10 by volume. Preferably, said ratio is selected between 1:12:4 and 1:18:7 by volume. According to a particularly preferred aspect, said ratio is 1:15:5 by volume .

[0047] According to another preferred aspect, the organic solvent referred to in step m' ) , m' ' ) or m' ' ' ) is preferably selected from esters or ethers. When the organic solvent is an ester, it is preferably selected between ethyl acetate and isopropyl acetate. When the organic solvent is an ether, it is preferably an ether of formula OR1R2, wherein the R1 and R2 groups are selected, independently of each other, between C1-C6 alkyl, linear or branched, and C3-C6 cycloalkyl. According to a preferred aspect, when the solvent is an ether, it is cyclopentyl methyl ether.

[0048] As regards steps m' ) and m' ' ) , preferably the hydrochloric acid is anhydrous hydrochloric acid dissolved in an organic solvent selected from alcohols, ethers, esters or mixtures thereof. When the anhydrous hydrochloric acid is dissolved in an alcohol, this is preferably selected from methanol, ethanol, isopropanol or mixtures thereof, more preferably the anhydrous hydrochloric acid is dissolved in isopropanol. When anhydrous hydrochloric acid is dissolved in an ether, this is preferably cyclopentyl methyl ether. When anhydrous hydrochloric acid is dissolved in an ester, this is preferably ethyl acetate, isopropyl acetate or mixtures thereof. According to a preferred aspect, the concentration of anhydrous hydrochloric acid in solvent is between 10-25% by weight, preferably the concentration of hydrochloric acid in isopropanol is 15- 19% by weight.

[0049] Advantageously, the addition of organic solvent in the step m' ) , m' ' ) , or m' ' ' ) allows the precipitation of the product to be obtained in reduced times and therefore the purity of the product is higher, since the possibility of formation of the impurities themselves.

[0050] As regards the isolation step p) , this step is preferably carried out by filtration.

[0051] According to a preferred aspect, the process of the invention further comprises a step q) : q) drying the solvate of formula II obtained in step p) under vacuum at a temperature comprised between 45°C and 60°C, preferably at a temperature comprised between 48 °C and 58°C, more preferably between 50°C and 55 °C.

[0052] According to another preferred aspect, the drying step q) takes place for a time comprised between 10 and 48 hours, preferably comprised between 12 and 24 hours.

[0053] According to another preferred aspect, the drying step q) takes place at a temperature comprised between 45°C and 60°C, preferably at a temperature comprised between 48°C and 58°C, more preferably between 50°C and 55°C, and for a time comprised between 10 and 48 hours, preferably comprised between 12 and 24 hours.

[0054] The above is intended as an example and not as a limitation. Furthermore, the person skilled in the art will be able to understand what modifications can be made without departing from the scope of the present invention . EXAMPLES

[0055] This description will be better illustrated in the following examples which are for illustrative and nonlimiting purposes only.

[0056] Example 1. Preparation of trilaciclib dihydrochloride acetic acid hemisolvate from trilaciclib trifluoro acetate.

[0057] 1 gram of trilaciclib trifluoroacetate was suspended in 6 ml of acetic acid at a temperature of 25°C. Subsequently, 1 g of a 17% HC1 solution in isopropanol was added. The suspension thus obtained was added to 12 ml of cyclopentylmethylether under stirring, maintaining the temperature of 25°C. At the end of the addition, the suspension obtained was kept under stirring for 5 minutes. Subsequently, the solid product was filtered and the cake was washed with 2 ml of cyclopentyl methyl ether. Finally, the resulting wet product was dried in a vacuum oven for 16 hours at 50 °C. The molar yield obtained was 88%.

[0058] Example 2. Preparation of trilaciclib dihydrochloride acetic acid hemisolvate from trilaciclib dihydrochloride .

[0059] 1 gram of trilaciclib dihydrochloride was suspended in 20 ml of a cyclopentylmethylether : acetic acid mixture with a ratio of 3:1 and kept under stirring at a temperature of 65°C for 24 hours; at the end of 24 hours the mass was brought back to room temperature (25°C) . The product obtained was filtered and the panel washed with 2 ml of cyclopentylmethylether. The crystal was then dried in an oven for 16 hours at 55°C. The molar yield obtained was 85%. Example 3. Preparation of trilaciclib dihydrochloride acetic acid hemisolvate from trilaciclib free base.

[0060] 1 gram of trilaciclib base was suspended in 20 ml of a cyclopentylmethylether : acetic acid mixture with a ratio of 3:1, kept under stirring at a temperature of 65°C for

[0061] 15 minutes and finally 1.43 g of HC1 were added in 17% IPA anhydrous; everything was left under stirring and at a temperature of 65°C for 24 hours. At the end of 24 hours the temperature was brought back to room temperature (25°C) . The product was filtered and the panel washed with 2 ml of cyclopentyl methyl ether. The crystal was then dried in an oven for 16 hours at 55°C. The molar yield obtained was 90%.

Claims

CLAIMS1. Trilaciclib dihydrochloride acetic acid hemisolvate of formula II in crystalline formFormula II having a characteristic XRPD dif f ractogram comprising at least one characteristic peak expressed in 2-Theta (20) values selected from 7.2°±0.2°, 14.5°±0.2°, 15.9°±0.2°, 18.2°±0.2°, 18.9°±0.2° and 22.1 °±0.20.

2. Trilaciclib according to claim 1, having a characteristic XRPD dif f ractogram comprising at least two characteristic peaks expressed in 2-Theta (20) values selected from 7.2°±0.2°, 14.5°±0.2°, 15.9 °±0.2°, 18.2°±0.2°, 18.9°±0.2° and 22.1 °±0.20.

3. Trilaciclib according to claim 1, having a characteristic XRPD dif f ractogram comprising at least three characteristic peaks expressed in 2-Theta (20) values selected from 7.2°±0.2°, 14.5°±0.2°, 15 ,9°±0.2°, 18.2°±0.2°, 18.9°±0.2° and 22.1 °±0.20.

4. Process for obtaining trilaciclib dihydrochloride acetic acid hemisolvate of formula II in crystalline formFormula IIas defined in any one of claims 1-3, comprising the steps of : a' ) suspending trilaciclib base in acetic acid and adding hydrochloric acid, obtaining a suspension of trilaciclib dihydrochloride, or a' ' ) suspending trilaciclib in the form of a salt in acetic acid, wherein said salt is not trilaciclib dihydrochloride, and adding hydrochloric acid, obtaining a suspension of trilaciclib dihydrochloride, or a' ' ' ) suspending trilaciclib dihydrochloride in acetic acid, obtaining a suspension of trilaciclib dihydrochloride ; b) adding the suspension of trilaciclib dihydrochloride obtained at point a' ) , a' ' ) or a' ' ' ) to an organic solvent so as to precipitate trilaciclib as trilaciclib solvate of formula II in crystalline form; c) isolating trilaciclib solvate of formula II in crystalline form.

5. Process according to claim 4, wherein the salt of step a' ' ) is trilaciclib trifluoroacetate.

6. Process according to any one of claims 4-5, wherein in step a' ) , a' ' ) or a' ' ' ) the ratio of trilaciclib to acetic acid is comprised between 1:4 and 1:8 by volume, preferably said ratio is comprised between 1:5 and 1:7.

7. Process according to any of claims 4-6, wherein the organic solvent referred to in step b) is selected from esters, preferably ethyl acetate or isopropyl acetate, and ethers, preferably an ether of formula 0R1R2, wherein R1 and R2 groups are independently selected from linear or branched C1-C6 alkyl and C3-C6 cycloalkyl.

8. Process for obtaining trilaciclib dihydrochloride acetic acid hemisolvate of formula II in crystalline formFormula II as defined in any one of claims 1-3, comprising the steps of : m' ) suspending trilaciclib base in a mixture of organic solvent and acetic acid and adding hydrochloric acid, obtaining a suspension of trilaciclib dihydrochloride, or m' ' ) suspending trilaciclib in the form of a salt in a mixture of organic solvent and acetic acid, wherein said salt is not trilaciclib dihydrochloride, and adding hydrochloric acid, obtaining a suspension of trilaciclib dihydrochloride, or m' ' ' ) suspending trilaciclib dihydrochloride in a mixture of organic solvent and acetic acid, obtaining a suspension of trilaciclib dihydrochloride; n) heating the suspension referred to in step m' ) , m' ' ) or m' ' ' ) to a temperature comprised between 50°C and 70°C, preferably comprised between 55°C and 65°C, to obtain a suspension; o) cooling the suspension according to step n) to a temperature comprised between 0°C and 30°C, preferably comprised between 15°C and 30°C, more preferably between 22°C and 28°C; p) isolating trilaciclib solvate of formula II in crystalline form.

9. Process according to claim 8, wherein the salt of step m' ' ) is trilaciclib trifluoroacetate.

10. Process according to claim 8 or 9, wherein the organic solvent referred to in step m' ) , m' ' ) or m' ' ' ) is selected from esters, preferably ethyl acetate or isopropyl acetate, and ethers, preferably ether of formula OR1R2, wherein R1 and R2 groups are selected from, independently of each other, linear or branched C1-C6 alkyl and C3-C6 cycloalkyl.

Citation Information

Patent Citations

  • Synthesis of n-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines

    WO2018005865A1

  • Morphic forms of trilaciclib and methods of manufacture thereof

    WO2021257587A1

  • Solid state forms of trilaciclib and of trilaciclib salts

    WO2022076779A1